RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with ...

Novel small interfering RNA (siRNA) agent lepodisiran drastically cut levels of lipoprotein(a), or Lp(a), in the phase II ALPACA trial. The 400-mg dose cut Lp(a) by 93.9 percentage points compared ...

Advanced Cell Diagnostics™, a Bio-Techne brand, provide research tools that alleviate the challenges of traditional techniques and have recently launched their miRNAscope™ Assay to detect antisense ...

Medical researchers are also studying ways to control expression of different proteins linked to various diseases by injecting manufactured dsRNA or antisense siRNA strands into cells (Whalley ...

Antisense technologies heralded a new era for ... realize that the field is still rapidly evolving, with new modes of siRNA action still emerging, so we are not setting the criteria for ...

The sense strand of siRNA is then removed from RISC, and the activated RISC with the antisense strand serves as a template for the binding of complementary mRNA, inducing mRNA degradation.

AstraZeneca's take on the PCSK9 inhibitor – an antisense drug licensed from Ionis ... notably Novartis' small interfering RNA (siRNA) therapy Leqvio (inclisiran), which only needs to be ...

The category of genetic medicine for cardiovascular disease based on siRNA and antisense oligonucleotides is gathering momentum, with a series of new medicines on, or nearing, the market.

Ribosomal profiling is also offered. Maintains sh/siRNA and antisense oligonucleotide capabilities for knock-down and gene editing of CFTR and other cellular targets relevant to CF pathogenesis ...

Decoys bind to transcription factors of targeted DNA at the earliest phase. Subsequently, antisense RNA, small interfering RNA (siRNA), and microRNA (miRNA) act to target mRNAs. Then, aptamers ...